We entered into these agreements within the rules of engagement, and I don't think these conversations we're having right now were part of the consideration of the rules of engagement at the time.
The context in which these agreements were entered into is very specific. The context in which these contracts were entered into in other countries, with the European Commission and in the U.S., where there was broader support in Moderna's case, are very different.